Life sciences companies face distinct challenges with their very visible role in drug pricing and access to medicines, and the pandemic only underscored this focus. Even during these unprecedented times over the last two years, many life sciences organisations have witnessed a scientific breakthrough. Shifts to more data-driven approaches across the value chain, greater collaborations, digital transformation, and the advancing CEO priorities are driving the change. A new bar has been set and companies are now willing to move beyond convention to solve the toughest challenges and stand to reap the biggest benefits.
Our 2022 Global Life Sciences Outlook focuses on the current state of the sector, explores seven trends shaping the industry and prepares stakeholders to take advantage of the many opportunities the pandemic has surfaced and accelerated. In the year ahead, forward-looking companies will adopt a think-digital-to-be-digital mindset and consider how these technologies can augment human capabilities and update execution of processes.
In 2022, as life sciences executives address the urgency for more investments and take more risks, digital technology and AI are expected to come together to change the status quo and transform functional areas and value streams. It’s time to take advantage of this technological momentum and lessons learned from the pandemic—operating by being digital and competing by being agile.
- Vicky Levy, Deloitte Global Life Sciences Sector Leader